| ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation G D’Uva, A Aharonov, M Lauriola, D Kain, Y Yahalom-Ronen, S Carvalho, ... Nature cell biology 17 (5), 627-638, 2015 | 640 | 2015 |
| Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor Y Enuka, M Lauriola, ME Feldman, A Sas-Chen, I Ulitsky, Y Yarden Nucleic acids research 44 (3), 1370-1383, 2016 | 560 | 2016 |
| Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals Y Zwang, A Sas-Chen, Y Drier, T Shay, R Avraham, M Lauriola, E Shema, ... Molecular cell 42 (4), 524-535, 2011 | 117 | 2011 |
| Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies V Gelfo, D Romaniello, M Mazzeschi, M Sgarzi, G Grilli, A Morselli, ... International journal of molecular sciences 21 (17), 6009, 2020 | 112 | 2020 |
| EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer M Kedmi, N Ben-Chetrit, C Körner, M Mancini, NB Ben-Moshe, M Lauriola, ... Science signaling 8 (368), ra29-ra29, 2015 | 75 | 2015 |
| Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer N Ben-Chetrit, D Chetrit, R Russell, C Koerner, M Mancini, A Abdul-Hai, ... Science Signaling 8 (360), ra7-ra7, 2015 | 69 | 2015 |
| Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment M Lauriola, Y Enuka, A Zeisel, G D’Uva, L Roth, M Sharon-Sevilla, ... Nature Communications 5 (1), 1-13, 2014 | 68 | 2014 |
| Modeling ductal carcinoma in situ: a HER2–Notch3 collaboration enables luminal filling CR Pradeep, WJ Köstler, M Lauriola, RZ Granit, F Zhang, J Jacob-Hirsch, ... Oncogene 31 (7), 907-917, 2012 | 61 | 2012 |
| Adenomatous polyposis coli (APC) regulates miR17-92 cluster through β-catenin pathway in colorectal cancer Y Li, M Lauriola, D Kim, M Francesconi, G D’Uva, D Shibata, MP Malafa, ... Oncogene 35 (35), 4558-4568, 2016 | 59 | 2016 |
| Estrogen receptors and melanoma: a review E Dika, A Patrizi, M Lambertini, N Manuelpillai, M Fiorentino, A Altimari, ... Cells 8 (11), 1463, 2019 | 53 | 2019 |
| SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors L Roth, S Srivastava, M Lindzen, A Sas-Chen, M Sheffer, M Lauriola, ... Science signaling 11 (515), eaan0949, 2018 | 53 | 2018 |
| Cardiotoxicity of anticancer drugs: Molecular mechanisms and strategies for cardioprotection MB Morelli, C Bongiovanni, S Da Pra, C Miano, F Sacchi, M Lauriola, ... Frontiers in Cardiovascular Medicine 9, 847012, 2022 | 49 | 2022 |
| The roadmap of colorectal cancer screening E Ferlizza, R Solmi, M Sgarzi, L Ricciardiello, M Lauriola Cancers 13 (5), 1101, 2021 | 47 | 2021 |
| Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection MT Rodia, G Ugolini, G Mattei, I Montroni, D Zattoni, F Ghignone, ... Oncotarget 7 (21), 30295, 2016 | 47 | 2016 |
| Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions CR Pradeep, A Zeisel, WJ Köstler, M Lauriola, J Jacob-Hirsch, ... Oncogene 31 (31), 3569-3583, 2012 | 44 | 2012 |
| A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors V Gelfo, MT Rodia, M Pucci, M Dall'Ora, S Santi, R Solmi, L Roth, ... Oncotarget 7 (44), 72167, 2016 | 43 | 2016 |
| IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn's disease and correlation with sub-phenotypes M Lauriola, G Ugolini, S RIvETTI, S Nanì, G Rosati, S Zanotti, I Montroni, ... International journal of molecular medicine 27 (3), 469-477, 2011 | 43 | 2011 |
| Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines R Solmi, M Lauriola, M Francesconi, D Martini, M Voltattorni, C Ceccarelli, ... BMC cancer 8, 1-22, 2008 | 40 | 2008 |
| AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer A Noronha, N Belugali Nataraj, JS Lee, B Zhitomirsky, Y Oren, S Oster, ... Cancer discovery 12 (11), 2666-2683, 2022 | 39 | 2022 |
| An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors S Carvalho, M Lindzen, M Lauriola, N Shirazi, S Sinha, A Abdul-Hai, ... Oncogene 35 (4), 438-447, 2016 | 39 | 2016 |
Gabriele D'UvaBologna University, ItalyVerified email at unibo.it
